Supha Pharmachem share price
BSE: 539561Commercial Services & SuppliesSmall Cap
Last close ₹0.24down ₹0.01 (4.00%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹0.25.
52-week range of traded prices to 23 Oct 2026
₹0.23Low, 22 Oct 2026₹1.66High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹21 Cr3,473rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day.
- 72,65,991
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Sep 2025, against the quarter beforeFiled 14 Nov
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8.58 Crdown 53.31%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.07 CrQuarter to Jun 2025: −₹0.37 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 0.9%
Revenue by year
Peak revenue ₹4,042 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Dec 2023Filed 26 Feb | Mar 2024Filed 25 Jun | Jun 2024Filed 19 Sep | Sep 2024Filed 14 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 4 Aug | Sep 2025Filed 14 Nov |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,834 | 1,408 | 78 | 25 | 38 | 82 | 18 | 9 |
| Net profit | 69 | −54 | 2 | 2 | 1 | −3 | 0 | 0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 3.7% | −3.8% | 2.1% | 7.1% | 2.0% | −3.2% | −2.0% | 0.9% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2025 the company reports one business segment, Trading of Chemicals, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2025, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −93.3% | −95.3% | +43.3% | 0.0% |
| 3 years | +13.7% | +12.4% | +1.2% | 0.0% |
| 5 years | +55.7% | +40.8% | +10.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Trading & Distributors, 196 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Supha Pharmachem in market cap.
Supha Pharmachem is not on the chart: it has no P/E or return on equity today
| Company | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 Sarthak IndustriesSARTHAKIND | 23 | 7.9 | 0.5 | 11.6 | +19.5% | −23.6% | 6.5% | 4.5% | – | – | 0.00% |
 Medico IntercontinentalMIL | 23 | – | 0.5 | 51.9 | −15.8% | −220.4% | −8.3% | −4.4% | – | – | 0.00% |
 Mahan IndustriesMAHANIN | 21 | – | 2.4 | – | +259.4% | – | – | – | 0.47% | 77.11% | 0.00% |
 Asian Tea & ExportsASIANTNE | 21 | 63.6 | 0.3 | 87.1 | +18.7% | +40.6% | 0.5% | 0.1% | – | – | 0.00% |
 Lesha IndustriesLESHAIND | 21 | 145.5 | 0.3 | – | −17.0% | – | 0.2% | −0.3% | – | – | 0.00% |
 Franklin IndustriesFRANKLININD | 21 | – | 0.2 | – | −87.8% | – | – | −22.8% | – | – | 0.00% |
 SBEC Systems (Ind)SBECSYS | 20 | 13.7 | – | 24.0 | +2.3% | −39.6% | – | 13.5% | – | – | 0.00% |
 Salora InternationalSALORAINTL | 20 | – | 0.4 | – | −74.7% | – | −9.6% | −3.7% | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record; for ROCE and EV/EBITDA, where the company is a lender or an insurer; for NIM and ROA, where the company does not file a lender's accounts. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page. ROA is the year's profit over average total assets. NIM is net interest income over average loans and investments.
Latest announcements
Routine notices left out.Share news and announcements
Jun 2026
30 Jun · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Regarding The Order Passed By Hon'Ble National Company Law Appellate Tribunal (NCLAT) Principal Bench, New Delhi
May 2026
Apr 2026
10 Apr · Corporate Insolvency Resolution Process (CIRP)-List of Creditors
2 Apr · Postponement Of Board Meeting Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Mar 2026
Supha Pharmachem share price by year
Each calendar year to 2025.Supha Pharmachem share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 0.75 | −85.4% | 6.13 | 0.75 |
| 2024 | 5.12 | −79.6% | 35.51 | 5.00 |
| 2023 | 25.07 | +1,895.6% | 42.78 | 1.23 |
| 2022 | 1.26 | +1.2% | 1.28 | 1.20 |
| 2021 | 1.24 | +194.2% | 1.24 | 0.36 |
| 2020 | 0.42 | +111.9% | 0.43 | 0.17 |
| 2019 | 0.20 | +35.2% | 0.20 | 0.13 |
| 2018 | 0.15 | – | 0.26 | 0.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 25 May 2018.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.24 | 0.24 | 72,65,991 |
| 22 Oct 2026 | 0.23 | 0.25 | 0.23 | 0.25 | 0.24 | 5,84,714 |
| 21 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.24 | 0.24 | 25,36,038 |
| 19 Oct 2026 | 0.25 | 0.25 | 0.24 | 0.25 | 0.25 | 16,48,125 |
| 16 Oct 2026 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 10,26,902 |
| 15 Oct 2026 | 0.26 | 0.26 | 0.24 | 0.24 | 0.25 | 23,17,324 |
| 14 Oct 2026 | 0.24 | 0.25 | 0.24 | 0.25 | 0.25 | 23,16,056 |
| 13 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.24 | 0.25 | 17,32,468 |
| 12 Oct 2026 | 0.26 | 0.26 | 0.25 | 0.25 | 0.25 | 14,71,755 |
| 9 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.26 | 0.25 | 8,92,730 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 15 Apr 2025 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 15 Apr 2025 | Price move | – | A corporate action went ex within three days of this move (Right Issue of Equity Shares, ex-date 15 Apr 2025), and its terms do not account for the move. Not adjusted for. |
| 5 Jul 2024 | Bonus | 0.2500 | Holders received 3 bonus shares for every 1 held. |
| 23 Feb 2024 | Split | 0.2000 | Each share became 5. |
| 1 Sep 2023 | Split | 0.5000 | Each share became 2. |
| 28 Jul 2023 | Bonus | 0.3571 | Holders received 9 bonus shares for every 5 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- SUPHA PHARMACHEM LIMITED
- BSE code
- 539561
- ISIN
- INE549S01036
- Industry
- Commercial Services & Supplies
- Listed
- Jan 2016
- Face value
- ₹1
- CIN
- L24100MH1988PLC343805
- Corporate identity number, the registrar of companies' code for it